Humanigen, Inc. (NASDAQ:HGEN) insider Edward P. Jordan sold 14,700 shares of the firm’s stock in a transaction that occurred on Tuesday, June 8th. The shares were sold at an average price of $20.08, for a total transaction of $295,176.00. Following the transaction, the insider now directly owns 14,700 shares in the company, valued at approximately $295,176. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of Humanigen stock opened at $21.07 on Friday. The business has a fifty day moving average of $18.12. The firm has a market capitalization of $1.24 billion, a P/E ratio of -6.22 and a beta of -2.39. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.85 and a current ratio of 1.85. Humanigen, Inc. has a 1 year low of $7.50 and a 1 year high of $33.95.
Humanigen (NASDAQ:HGEN) last announced its quarterly earnings data on Thursday, May 13th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61). On average, analysts anticipate that Humanigen, Inc. will post 3.45 earnings per share for the current year.
Several equities analysts recently weighed in on HGEN shares. JPMorgan Chase & Co. started coverage on shares of Humanigen in a research report on Tuesday, February 23rd. They set a “neutral” rating and a $21.00 price objective on the stock. Zacks Investment Research lowered shares of Humanigen from a “hold” rating to a “sell” rating in a research report on Wednesday, May 19th. Roth Capital raised their price objective on shares of Humanigen from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, May 5th. Oppenheimer initiated coverage on shares of Humanigen in a research report on Thursday, May 6th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 price target (up previously from $34.00) on shares of Humanigen in a report on Monday, April 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Humanigen currently has an average rating of “Buy” and a consensus target price of $30.14.
Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia.
Recommended Story: Return on Equity (ROE)
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.